Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-rectal Botulinum Toxin for Non-retentive Fecal Incontinence in Children
NCT06785844Phase 1Recruiting
- Sponsor
- Shaare Zedek Medical Center
- Start
- Jul 2025
- Primary completion
- Sep 2030
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of botulinum toxin type A in fecal incontinence (FI), sponsored by Shaare Zedek Medical Center. Primary endpoint: Median number of fecal incontinence episodes per week at 1 month. Started Jul 2025; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
fecal incontinence (FI)
Beyond the preview
Go deeper on NCT06785844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06785844.